This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABX-IL8
Description: ABX-IL8 is a XenoMouse-derived monoclonal antibody that binds to interleukin 8 (IL-8). It was previously in phase II trials for the treatment of psoriasis, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis (RA). These diseases, along with reperfusion injury and inflammatory bowel disease, share IL-8-mediated auto-inflammation as a part of theirpathogenesis.
Due to poor results in psoriasis and equivocal results in other trials, Abgenix has suspended development of this agent. It is possible that the agent will one day be resurrected if new pre-clinical data suggest new treatment regimens or indications or when pharmacogenomics or other molecular profiling methods mature to the point of efficiently distinguishing ABX-IL8 responders from non-responders. Alternately, Abgenix may develop another anti-IL8 monoclonal antibody that proves more efficacious than this one.
Additional information available to subscribers only: